1
|
Klink AJ, Gajra A, Knoth RL, Marshall L, Hou Y, McBride A, Copher R. Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946]. Leuk Res 2024; 136:107430. [PMID: 38199929 DOI: 10.1016/j.leukres.2023.107430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2024]
Affiliation(s)
- Andrew J Klink
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | - Ajeet Gajra
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | | | - Landon Marshall
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | - Ying Hou
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | - Ali McBride
- Brystol Meyers Squibb, 86 Morris Avenue, Summit, NJ, USA.
| | - Ronda Copher
- Brystol Meyers Squibb, 86 Morris Avenue, Summit, NJ, USA
| |
Collapse
|
2
|
Knoth RL, Gupta S, Perkowski K, Costantino H, Inyart B, Ashka L, Clapp K. Understanding the Association between Red Blood Cell Transfusion Utilization and Humanistic and Economic Burden in Patients with β-Thalassemia from the Patients' Perspective. J Clin Med 2023; 12:jcm12020414. [PMID: 36675342 PMCID: PMC9861260 DOI: 10.3390/jcm12020414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 12/23/2022] [Indexed: 01/06/2023] Open
Abstract
We assessed the humanistic and economic burden of chronic red blood cell (RBC) transfusions on patients with β-thalassemia. This cross-sectional, US-based study included adults (≥18 years) who self-reported a β-thalassemia physician diagnosis and had received ≥1 RBC transfusion in the past 6 months. The outcomes included the Functional Assessment of Cancer Therapy-Anemia (FACT-An), Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and ad hoc questions about treatment experience, side effects, direct/indirect costs, and psychological burden. Overall, 100 patients completed the survey, of whom 70% experienced "moderate" to "extremely high" burden due to RBC transfusions, 81% reported iron overload, 42% reported compromised social lives. The mean FACT-An score was 132 (higher score indicates better outcomes; 0-188). Mean scores were 33/52 for fatigue and 20/28 for anemia symptoms in the previous 7 days. Health-related quality of life (HRQoL) temporarily improved after RBC transfusion, although patients continued to experience mild-to-severe depression and anxiety, substantial direct costs, compromised employment, and suboptimal quality of life. Over 6 months, patients dedicated a mean of 173 h to transfusion requirements and incurred out-of-pocket costs of USD 2239 for transfusions and USD 896 for additional care costs. These findings highlight the need for new treatment options to improve patient HRQoL and economic outcomes.
Collapse
Affiliation(s)
- Russell L Knoth
- Bristol Myers Squibb, 100 Nassau Park Blvd #300, Princeton, NJ 08540, USA
| | - Shaloo Gupta
- Cerner Enviza, an Oracle Company, 51 Valley Stream Pkwy, Malvern, PA 19355, USA
| | - Kacper Perkowski
- Cerner Enviza, an Oracle Company, 51 Valley Stream Pkwy, Malvern, PA 19355, USA
| | - Halley Costantino
- Cerner Enviza, an Oracle Company, 51 Valley Stream Pkwy, Malvern, PA 19355, USA
| | - Brian Inyart
- Cerner Enviza, an Oracle Company, 51 Valley Stream Pkwy, Malvern, PA 19355, USA
| | - Lauren Ashka
- Cerner Enviza, an Oracle Company, 51 Valley Stream Pkwy, Malvern, PA 19355, USA
| | - Kelly Clapp
- Cerner Enviza, an Oracle Company, 51 Valley Stream Pkwy, Malvern, PA 19355, USA
| |
Collapse
|
3
|
Klink AJ, Gajra A, Knoth RL, Marshall L, Hou Y, McBride A, Copher R. Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. Leuk Res 2022; 122:106946. [PMID: 36108427 DOI: 10.1016/j.leukres.2022.106946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 08/26/2022] [Accepted: 09/01/2022] [Indexed: 11/17/2022]
Abstract
Enasidenib was approved by the Food and Drug Administration in 2017 for the treatment of patients with relapsed or refractory (RR) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Given limited data in clinical practice, this study assessed real-world clinical outcomes and healthcare resource use in patients with RR AML. Physicians performed chart abstraction of patients with RR IDH2-mutated AML treated with enasidenib (between 1/2018 and 6/2019) or other first-line (1 L) RR therapy (between 1/2016 and 7/2017). Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method, and adjusted risk of progression and death were estimated by multivariable Cox proportional hazard models. Among 124 patients treated with enasidenib and 76 patients treated with other 1 L RR therapy, overall response rate was higher among patients treated with enasidenib vs. other 1 L RR therapies (77% vs. 52%, p < 0.01). After a median follow-up of 9 and 6 months, median PFS was 8 months in enasidenib-treated patients and 5 months in patients receiving other 1 L RR therapy, respectively (adjusted HR=0.36, 95% CI: 0.23-0.57, p < 0.01). Median OS was 11 and 6 months in enasidenib-treated patients and patients receiving other 1 L RR therapy, respectively (adjusted HR=0.37, 95% CI: 0.22-0.60, p < 0.01). Fewer enasidenib-treated patients were hospitalized during 1 L RR therapy vs. those receiving other therapies (14% vs. 46%, p < 0.01). Results from this real-world study confirm the effectiveness of enasidenib among patients with IDH2-mutated RR AML and demonstrate that hospitalizations were significantly lower vs. other 1 L RR treatment in clinical practice.
Collapse
Affiliation(s)
- Andrew J Klink
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | - Ajeet Gajra
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | | | - Landon Marshall
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | - Ying Hou
- Cardinal Health Specialty Solutions, 7000 Carinal Place, Dublin, OH, USA
| | - Ali McBride
- Bristol Myers Squibb, 86 Morris Avenue, Summit, NJ, USA.
| | - Ronda Copher
- Bristol Myers Squibb, 86 Morris Avenue, Summit, NJ, USA
| |
Collapse
|
4
|
Huggar D, Knoth RL, Copher R, Cao Z, Lipkin C, McBride A, LeBlanc TW. Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy. Future Oncol 2022; 18:3609-3621. [PMID: 36305495 DOI: 10.2217/fon-2022-0706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Aim: This retrospective, observational study assessed healthcare resource utilization (HCRU) and costs for newly diagnosed acute myeloid leukemia (AML) patients receiving intensive induction chemotherapy. Materials & methods: Adult AML patients with inpatient hospitalization or hospital-based outpatient visit receiving intensive induction chemotherapy (CPX-351 or 7 + 3 treatments) were identified from the Premier Healthcare Database (US). Results: All 642 patients had inpatient hospitalizations (median number = 2; median length of stay = 16 days); 22.4% had an ICU admission. Median total outpatient hospital cost was US$2904 per patient, inpatient hospital cost was $83,440 per patient, and ICU cost was $16,550 per patient. Discussion: In the US hospital setting, substantial HCRU and costs associated with intensive induction chemotherapy for AML were driven by inpatient hospitalizations.
Collapse
Affiliation(s)
| | | | | | - Zhun Cao
- Premier Inc., Charlotte, NC 28277, USA
| | | | | | | |
Collapse
|
5
|
Faught E, Li X, Choi J, Malhotra M, Knoth RL. Real-world analysis of hospitalizations in patients with epilepsy and treated with perampanel. Epilepsia Open 2021; 6:645-652. [PMID: 34170633 PMCID: PMC8633480 DOI: 10.1002/epi4.12515] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Revised: 05/26/2021] [Accepted: 05/30/2021] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVES (1) To evaluate risk of hospitalization following initiation of perampanel (pre- and post-analysis) and (2) to compare hospitalization rates following initiation of perampanel vs lacosamide. METHODS Patients were identified from Symphony Health's Patient Integrated Database if they had a prescription for perampanel (July 1, 2014-June 30, 2016). Patients 4-11 years of age with any partial-onset seizure (POS) or ≥12 years of age with any POS or primary generalized tonic-clonic seizure (GTCS) (pre-post); or ≥12 years of age (perampanel vs lacosamide). The first fill of perampanel ("index date") marked the start of the analysis period. Patients had ≥1 additional fill for perampanel and ≥2 diagnoses for epilepsy or nonfebrile convulsion diagnosis during pre-index (based on ICD-9/ICD-10 codes). Patients were matched using a 1:1 propensity scoring method for the perampanel vs lacosamide analysis. Primary outcome was hospitalization during the one year following medication initiation. RESULTS Pre- and post-perampanel: N = 1771 (mean age 34 years, 55% female). One-year all-cause hospitalization risk ratio was 0.76 (P < .05) and 36.2% with hospitalization during the pre-period vs 29.5% in the follow-up. One-year epilepsy-related inpatient hospitalization risk ratio was 0.72 (P < .05) and 30.8% with hospitalization during the pre-period vs 23.9% during follow-up. In the perampanel and lacosamide cohorts, N = 1717 per cohort after matching, most baseline demographics were balanced. A higher percentage of subjects were prescribed ≥3 anti-seizure medications for perampanel vs lacosamide (60.5% vs 57.7%, P < .001). The perampanel cohort had a 9.6% reduction in all-cause hospitalizations vs 5.8% for the lacosamide cohort (P < .05). Epilepsy-related hospitalizations decreased from the pre-index rate by 9.9% for perampanel and 8.3% for lacosamide (P < .05). Among those with baseline hospitalizations, perampanel was associated with a 59.9% reduction in all-cause hospitalizations vs 48.6% for lacosamide (P < .05), and for epilepsy-related hospitalizations, a reduction of 65.0% vs 58.9%, respectively (P < .05). SIGNIFICANCE Perampanel was associated with a significant reduction in one-year hospitalization risk.
Collapse
Affiliation(s)
- Edward Faught
- Department of Neurology, Emory University, Atlanta, GA, USA
| | - Xuan Li
- Eisai Inc., Woodcliff Lake, NJ, USA
| | | | | | | |
Collapse
|
6
|
Hussain SA, Ortendahl JD, Bentley TGK, Harmon AL, Gupta S, Begley CE, Khilfeh I, Knoth RL. The economic burden of caregiving in epilepsy: An estimate based on a survey of US caregivers. Epilepsia 2020; 61:319-329. [PMID: 31953846 DOI: 10.1111/epi.16429] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Revised: 12/24/2019] [Accepted: 12/24/2019] [Indexed: 12/15/2022]
Abstract
OBJECTIVE The burden of caregiving for persons with epilepsy (PWEs) has not been examined previously in the United States. We assessed the clinical impact and direct and indirect economic costs for caregivers of PWEs. METHODS An internet survey of 500 caregivers of PWEs was conducted from May to July 2015 using a combination of validated instruments and questions designed specifically for this survey. Caregivers were stratified by PWE age (adult/child) and disease severity (low: 0 vs high: 1 + seizures in the prior month). Annual self-reported direct and indirect costs were reported per caregiver and extrapolated to all US caregivers. The economic burden of caregiving for PWEs was defined as the difference between costs for caregivers and the general population. RESULTS Caregivers reported that PWEs averaged 11.4 seizures in the prior month. Eighty percent of respondents were female and the average age was 44.3. Since becoming a caregiver, many reported anxiety (52.8%), depression (41.0%), and insomnia (30.8%). Annual mean direct medical costs for caregivers of children with low vs high seizure frequency were $4344 and $10 162, respectively. Costs for caregivers of adult PWEs were $4936 and $8518. Mean indirect costs associated with caregiving for a child with low vs high seizure frequency were $20 529 and $40 137; those for caregivers of an adult were $13 981 and $28 410. The cost estimates are higher vs the general US population; annual per-person healthcare utilization costs were $2740 and productivity loss costs were $5015. When extrapolating to the US population of PWE caregivers, annual costs exceeded $62 billion vs $14 billion for the general population, resulting in a caregiver burden of nearly $48 billion. SIGNIFICANCE The clinical and economic burden of caregivers for PWE were substantial, and greatest for those caring for children with frequent seizures. The impact on caregivers should be considered when estimating the value of interventions that control epilepsy.
Collapse
Affiliation(s)
- Shaun A Hussain
- Division of Pediatric Neurology, UCLA Mattel Children's Hospital and David Geffen School of Medicine, Los Angeles, California
| | - Jesse D Ortendahl
- Partnership for Health Analytic Research, LLC, Beverly Hills, California
| | - Tanya G K Bentley
- Partnership for Health Analytic Research, LLC, Beverly Hills, California
| | - Amanda L Harmon
- Partnership for Health Analytic Research, LLC, Beverly Hills, California
| | | | | | | | | |
Collapse
|
7
|
Cramer JA, Yan T, Tieu R, Knoth RL, Fincher C, Malhotra M, Choi J. Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. Epilepsy Behav 2020; 102:106634. [PMID: 31783318 DOI: 10.1016/j.yebeh.2019.106634] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 09/19/2019] [Accepted: 09/28/2019] [Indexed: 11/28/2022]
Abstract
INTRODUCTION While antiepileptic drugs (AEDs) remain the primary treatment for epilepsy, many patients continue to have seizures. Uncontrolled seizures may be related to AED half-life, since short half-life (SHL) AEDs require more frequent dosing compared with the simplified regimens of long half-life (LHL) AEDs. Long half-life AEDs may also improve seizure control by extending missed dose forgiveness periods. The value of LHL AEDs may be assessed as reduced healthcare utilization. The study's objective was to examine the impact of adding an LHL versus SHL adjunctive AED on the risk of hospitalizations in patients with uncontrolled epilepsy. METHODS This was a retrospective, longitudinal cohort study using the Symphony Health Solution Patient Integrated Dataverse. Patients ≥12 years old with uncontrolled epilepsy (≥2 medical claims ≥30 days apart) were identified during a study period (8/1/2012-7/31/2017). Patients were selected if they were subsequently initiated an adjunctive AED (excluding modified release formulations), and the prescription date served as the index. Patients were stratified into two mutually exclusive cohorts based on the index AED half-life (≤20 versus >20 h). Poisson regressions with robust error variances were performed for the relative risks (RRs) of all-cause, epilepsy-related, and injury-related hospitalizations. RESULTS A total of 4984 patients were identified (2705 in the LHL and 2279 in the SHL cohort). Compared with those in the SHL cohort, patients in the LHL cohort were significantly younger [mean (SD, years): 43.9 (18.5) versus 49.2 (17.2), p < 0.001] and were less comorbid [mean (SD) of Charlson comorbidity index: 1.2 (1.8) versus 1.8 (2.2), p < 0.001]. In the one-year postindex date, adjusting for group differences, the risks of both all-cause and epilepsy-related hospitalizations were significantly lower in the LHL cohort than in the SHL cohort [all-cause: 0.84 (95% CI: 0.76-0.93), p = 0.0006; epilepsy-related: 0.83 (0.73-0.94), p = 0.0046].Injury-related hospitalizations did not differ between LHL and SHL cohorts. CONCLUSION In patients with uncontrolled epilepsy who were initiated on an adjunctive AED, the choice of an LHL versus SHL was associated with significantly lower risks of all-cause and epilepsy-related hospitalizations.
Collapse
Affiliation(s)
| | - Tingjian Yan
- Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Ste. 404, Beverly Hills, CA 90212, USA
| | - Ryan Tieu
- Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Ste. 404, Beverly Hills, CA 90212, USA
| | | | | | - Manoj Malhotra
- Eisai Inc., 100 Tice Blvd., Woodcliff Lake, NJ 07677, USA
| | - Jiyoon Choi
- Eisai Inc., 100 Tice Blvd., Woodcliff Lake, NJ 07677, USA.
| |
Collapse
|
8
|
Mougalian SS, Feinberg BA, Wang E, Alexis K, Chatterjee D, Knoth RL, Nero D, Miller T, Liassou D, Kish JK. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy. Future Oncol 2019; 15:3935-3944. [PMID: 31660764 DOI: 10.2217/fon-2019-0537] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Aim: To examine the effectiveness of eribulin mesylate for metastatic breast cancer post cyclin-dependent kinase inhibitor (CDKi) 4/6 therapy. Materials & methods: US community oncologists reviewed charts of patients who had received eribulin from 3 February 2015 to 31 December 2017 after prior CDKi 4/6 therapy and detailed their clinical/treatment history, clinical outcomes (lesion measurements, progression, death) and toxicity. Results: Four patient cohorts were created according to eribulin line of therapy: second line, third line, per US label and fourth line with objective response rates/clinical benefit rates of 42.2%/58.7%, 26.1%/42.3%, 26.7%/54.1% and 17.9%/46.4%, respectively. Median progression-free survival/6-month progression-free survival (79.5% of all patients censored) by cohort was: 9.7 months/77.3%, 10.3 months/71.3%, not reached/70.4% and 4.0 months/0.0%, respectively. Overall occurrence of neutropenia = 23.5%, febrile neutropenia = 1.3%, peripheral neuropathy = 10.1% and diarrhea = 11.1%. Conclusion: Clinical outcome and adverse event rates were similar to those in clinical trials and other observational studies. Longer follow-up is required to confirm these findings.
Collapse
Affiliation(s)
| | | | - Edward Wang
- Formerly with Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ 07677, USA
| | - Karenza Alexis
- Formerly with Eisai, Inc., Medical Affairs, Woodcliff Lake, NJ 07677, USA
| | - Debanjana Chatterjee
- Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ 07677, USA
| | - Russell L Knoth
- Formerly with Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ 07677, USA
| | - Damion Nero
- Cardinal Health Specialty Solutions, Dublin, OH 43017, USA
| | - Talia Miller
- Cardinal Health Specialty Solutions, Dublin, OH 43017, USA
| | | | | |
Collapse
|
9
|
Abstract
155 Background: Nausea and vomiting (NV) are tracked by CMS as 2 of 10 top drivers of potentially avoidable hospital admissions for patients with cancer. These admissions pose a savings opportunity, yet limited literature exists on the costs of chemotherapy-induced NV (CINV). Burke’s 2010 assessment of 19,139 patients from 2004-2007 found CINV hospitalizations cost $7,448 and comprised the majority of overall CINV events and costs vs ambulatory events. Rashid (2016) evaluated 1,682 patients with metastatic breast cancer from 2007-2011 and found CINV admissions cost $10,074 in 2013 US dollars. Using data from the US Agency for Healthcare Research and Quality ’s Healthcare Cost and Utilization Project website (HCUPnet), and after applying adjustment factors from recent literature, we evaluated the cost of NV hospitalizations. Methods: Data on US hospital discharges for NV (based on primary discharge diagnosis) were obtained for 2014 from HCUPnet. Charges were adjusted using Smith’s (2015) model showing commercial insurers paid 48.7% of their hospital charges. They were further modified to include professional fees equaling 26.4% of facilities paid amounts, as reported by Peterson (2015). The CPI-Medical rate was used to adjust costs to 2016 dollars. A US payer perspective was used. The proportion of total NV discharges due to CINV is not known; it is also unknown whether charges for CINV differ from those for NV overall. Results: HCUPnet reported 37,730 hospital discharges for NV, with mean charges of $23,603 per event. The mean payment to hospitals, after adjustment to reflect amounts insurers actually paid, was estimated at $11,232 per event. Adding physicians’ professional fees incurred in the hospital setting yet normally charged separately yielded a total hospitalization cost of $14,197 ($15,120 in 2016 US dollars). Conclusions: Hospitalization for NV is common and costly; adjusted paid amounts averaged > $15,000 per discharge, a level consistent with the CINV literature. This economic impact, in addition to the consequences for patients’ quality of life, suggests the need for continued advances in preventing CINV and optimizing compliance with national antiemetic guidelines, particularly for chemotherapy with high emetogenic potential.
Collapse
Affiliation(s)
- Eric Roeland
- University of California San Diego Moores Cancer Center, La Jolla, CA
| | - Joseph Ma
- University of California San Diego, Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA
| | | | | | | | | | | |
Collapse
|
10
|
Bentley TGK, Cohen JT, Elkin EB, Huynh J, Mukherjea A, Neville TH, Mei MG, Copher R, Knoth RL, Popescu I, Lee J, Zambrano J, Broder M. Validity and reliability of four value frameworks for cancer drugs. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.6603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6603 Background: Little is known about the validity and reliability of value assessment frameworks. Methods: Eight panelists used the ASCO, ESMO, ICER, and NCCN frameworks to conduct value assessments of 15 drugs for advanced lung and breast cancers and castration refractory prostate cancer. Panelists received instructions and published clinical data to complete the assessments, assigning each drug a numeric or letter score. We used Kendall’s W coefficient to measure convergent validity by cancer type among frameworks and intraclass correlation coefficients (ICC) to measure framework inter-rater reliability across cancers. Panelists were surveyed on their experiences. Results: Kendall’s W for breast, lung, and prostate cancer drugs were 0.560 ( p= 0.010), 0.562 ( p= 0.010), and 0.920 ( p< 0.001), respectively. Pairwise and subdomain W are shown in the table. ICC (95% CI) for ASCO, ESMO, ICER, and NCCN were 0.800 (0.660-0.913), 0.818 (0.686-0.921), 0.652 (0.466-0.834), and 0.153 (0.045-0.371), respectively. Panelists generally agreed the frameworks were logically organized and easy to use. Conclusions: Convergent validity among the frameworks was fair to excellent, increasing with clinical benefit subdomain concordance and simplicity of drug trial data. Inter-rater reliability, highest for ASCO and ESMO, improved with clarity of instructions and specificity of score definitions. Continued use, analyses, and refinements of the frameworks will bring us closer to using value-based treatment decisions to improve patient care and outcomes. [Table: see text]
Collapse
Affiliation(s)
- Tanya GK Bentley
- Partnership for Health Analytic Research, LLC, Beverly Hills, CA
| | | | | | - Julie Huynh
- Harbor University of California Los Angeles Medical Center, Redondo Beach, CA
| | - Arnab Mukherjea
- Health Sciences Program, California State University, Hayward, CA
| | - Thanh H. Neville
- David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
| | | | | | | | - Ioana Popescu
- David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
| | - Jackie Lee
- Partnership for Health Analytic Research, LLC, Beverly Hills, CA
| | - Jenelle Zambrano
- Partnership for Health Analytic Research, LLC, Beverly Hills, CA
| | - Michael Broder
- Partnership for Health Analytic Research, LLC, Beverly Hills, CA
| |
Collapse
|
11
|
Copher R, Knoth RL, Magee G, Misir S, McBride A. Chemotherapy induced nausea and vomiting in breast cancer treated with antiemetic prophylaxis as recommended by the ASCO antiemesis guidelines. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.10109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10109 Background: Current ASCO Antiemesis Guidelines recommend triple antiemetic therapy (a 5HT3RA, an NK1, and dexamethasone) to prevent chemotherapy (CT) induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC). This study evaluated whether this regimen resulted in reduced rates of CINV in patients diagnosed with breast cancer (BC) and initiated on HEC. The primary outcomes of interest were rates of acute and delayed CINV in patients whose antiemesis prophylaxis was or was not in accordance with the ASCO guideline (i.e., Per-guideline vs. Non-Guideline). Costs of treating CINV were also calculated. Methods: Patients were identified in the Premier Healthcare database, a complete geographically diverse census of inpatients and hospital-based outpatients. Adults treated for BC with HEC during the years 2012-14 were identified and stratified based on their antiemesis prophylaxis. Rates of acute (day of CT) and delayed CINV (days 2-7 post CT) were calculated following initiation of HEC. CINV was defined by ICD9 codes for nausea and vomiting or volume depletion/dehydration or use of a rescue antiemetic. Rates of CINV and health care costs were then compared between the two cohorts. Results: A total of 8,388 patients were included in the analysis. Of these, 5,447 (65%) had treatment Per-Guideline and 2,941 (35%) were Non-Guideline. For acute CINV, Per-Guideline patients had a significantly lower rate of CINV when compared to Non-Guideline patients (1.7% vs. 3.2%, respectively, p < .001). Similarly, in delayed CINV Per-Guideline patients had significantly lower rates of CINV when compared to Non-Guideline patients (15.4% vs. 19.1%, p < .001). Patients who experienced CINV also had significantly greater total health care costs versus those without CINV ($32,199 vs. $20,163, respectively, p < .001). Conclusions: The results showed adherence to the ASCO Antiemesis Guidelines led to lower rates of CINV and lower costs. Although defining CINV by claims may tell an incomplete story, this study suggests that following the ASCO Antiemesis Guidelines may help both patients and payers of health care costs.
Collapse
Affiliation(s)
| | | | | | | | - Ali McBride
- University of Arizona Cancer Center, Tucson, AZ
| |
Collapse
|
12
|
Benassi VA, Knoth RL, Mahler HIM. Detection of Noncontingency in a Free-Operant Situation. Pers Soc Psychol Bull 2016. [DOI: 10.1177/0146167285113001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Two experiments are presented that demonstrate college students' success at detecting response-noncontingent outcomes. Both experiments used free-operant procedures. In Experiment 1, subjects were randomly assigned to either response-contingent or response-noncontingent outcome conditions that produced the same frequency and temporal distribution of outcomes. The procedures differed only in terms of whether responses produced outcomes. Behavioral and verbal judgment data indicated that subjects in the response-noncontingent outcome condition detected the noncontingency. Experiment 2 investigated the outcome frequency variable. Prior experiments have shown that, under certain conditions, higher frequencies of response-noncontingent outcomes produce higher degrees of perceived control over those outcomes; other experiments have failed to find a similar outcome frequency effect. We gave two groups of subjects different frequencies of response-noncontingent outcomes. Results showed that response rates, but not judgments of control, were reliably influenced by this manipulation. We relate these findings to previous free-operant and trial-by-trial studies of noncontingency detection.
Collapse
|
13
|
Agatep BC, Faria C, Knoth RL, Chapman RH, Inocencio TJ, Johnsrud M, Powers A. Investigating rates of CINV across settings of care in Medicare: A retrospective claims-based analysis. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.30_suppl.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
297 Background: Clinical practice may differ according to settings of care and may impact both the quality of care delivered and, ultimately, patient outcomes. This study describes the differences in chemotherapy-induced nausea and vomiting (CINV) rates between chemotherapy (CT) naïve Medicare cancer patients starting CT in a hospital outpatient (HOP) or community outpatient (COP) setting. Methods: Using the 5% Medicare Fee-for-Service standard analytic files, patients with a new claim of CT and ≥1 outpatient cancer diagnosis claim between 1/1/10 – 6/30/11 were identified. Patients with a previous inpatient cancer diagnosis, multi-day CT cycles or who switched CT relevant to emetogenic potential were excluded. CINV was defined using relevant claims-based ICD-9-CM diagnosis and procedure codes within days 2-7 of the first 8 single-day CT cycles or the first 6 months following the index CT claim. CINV events were evaluated descriptively and using regression models. Results: Medicare patients receiving CT in HOP (n=1,007) vs. COP (n=1,080) were similar in demographics such as age, race, and baseline healthcare costs. However, Medicare patients receiving CT in COP compared to those in HOP settings were more likely to be female (57.0% vs. 44.7%), breast cancer patients (27.6% vs. 16.0%), live in the South region (37.7% vs. 32.3%), have higher Charlson Comorbidity Index scores (mean 5.2 vs. 4.8) and receive moderately to highly emetogenic CT (44.1% vs. 36.0%) (all p<0.05). Overall, 13.9% had any CINV in the evaluation period. More CINV events per patient were reported among those in COP compared to those in HOP settings (0.43 vs 0.27, p <0.05). However, differences between settings of care were not shown to be significantly different in adjusted regression analyses (p=0.177). Conclusions: We found the population characteristics between Medicare patients treated with CT in HOP and COP to vary on a number of factors. However, after controlling for these differences, our results suggest the number of CINV events was similar across settings of care. Future research should further clarify how differences in quality of care for antiemesis between COP and HOP settings may impact the incidence of CINV events in this population.
Collapse
|
14
|
Inocencio TJ, Faria C, Knoth RL, Chapman RH, Agatep BC, Johnsrud M, Powers A. Understanding the impact of settings of care and the development of chemotherapy-induced nausea and vomiting within a population of commercially insured patients. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.30_suppl.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
298 Background: Research evaluating the impact of different clinical practice patterns according to settings of care and oncology patient outcomes is limited. This study describes chemotherapy-induced nausea and vomiting (CINV) rates in chemotherapy (CT) naïve cancer patients starting CT in a hospital outpatient (HOP) or community outpatient (COP) setting. Methods: Using the Optum Normative Health Information Database, patients with a new claim of CT and ≥1 outpatient cancer diagnosis claim between 1/1/06 – 6/30/12 were identified. Patients with previous inpatient cancer diagnoses, multi-day CT regimens or Medicare/Medicaid patients were excluded. CINV was defined using relevant claims-based ICD-9-CM diagnosis and procedure codes or a prescription claim for antiemetics within days 2-7 of 1st 8 CT cycles or 1st 6 months following the index CT claim. CINV events were evaluated descriptively and using regression models Results: Patients receiving CT in HOP vs. COP were similar in age. Patients receiving CT in COP vs. HOP setting were more likely to be female (78.7% vs. 62.8%), breast cancer patients (66.8% vs. 46.7%), live in the South region (49.7% vs. 44.1%) and have higher baseline healthcare costs (mean $24,950 vs. $24,629) (all p<0.05). Patients in the HOP vs. COP settings had higher Charlson Comorbidity Index scores (mean 3.9 vs. 3.3, p < 0.05). More CINV events were reported for patients in COP vs. those in HOP settings (p < 0.05) (Table). After adjusting for clinical and demographic factors, number of CINV events remained higher for COP vs. HOP settings. However, we were unable to control for antiemetic prophylaxis use or CT emetogenic potential, due to coding irregularities. Conclusions: Results suggest cancer patients starting CT in COP vs. HOP settings may have more CINV events. However, further analyses are needed to explore the impact of antiemetic prophylaxis use or CT emetogenic potential on CINV events between settings of care. [Table: see text]
Collapse
|
15
|
Rugo HS, Palli S, Grabner M, Quimbo RA, Knoth RL. The impact of 5HT3RA antiemetics on the incidence of chemotherapy-induced nausea and vomiting (CINV), treatment adherence, and delay of therapy in early-stage breast cancer (BC) patients treated with moderately/highly emetogenic chemotherapy (MEC/HEC). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.27_suppl.75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
75 Background: The effectiveness of 5-HT3receptor antagonists (5HTs) for the prevention of CINV is well established. Less is known about the impact of these drugs on chemotherapy adherence (AD) and preventing delayed therapy (DT). We examined the impact of palonosetron (PAL) vs. other 5HTs on CINV incidence, treatment AD and DT in early-stage BC. Methods: An observational nested case-control study was conducted using the HealthCore Integrated Research Database (HIRD). Female patients (pts) were identified by their first claim for IV MEC/HEC between 1/1/02 and 10/31/10 (index). Inclusion criteria were: ≥ 12 months health plan eligibility pre-index (baseline) and ≥ 6 months post-index (follow-up); ≥ 1 baseline claim for BC; no claim for secondary or multiple primary neoplasms; and ≥ 1 claim for 5HT during follow-up. CINV was defined using ICD-9 codes for nausea, vomiting, or related events, and use of rescue medications for 5 days after MEC/HEC. AD was defined as receiving the requisite number of cycles within the recommended NCCN timeframe. DT was defined as exceeding 2x the NCCN-recommended cycle length between MEC/HEC claims. Outcomes were assessed using descriptive analysis and multivariate logistic regression, controlling for demographics, baseline medical conditions, and index therapy. Results: We identified 682/696 [MEC] and 1,782/3,103 [HEC] pts who received PAL or other 5HTs, respectively. For PAL vs. 5HT, 33.7% vs. 49.7% (OR: 0.51; 95% CI 0.41-0.65; p<0.01) had CINV (mean 0.27 vs. 0.61 events/cycle) in the MEC group; in the HEC group, 27.3% vs. 35.7% (OR: 0.61; 95% CI 0.53-0.7; p<0.01) had CINV (mean 0.21 vs. 0.34 events/cycle). PAL users delayed MEC at a lower rate than those using other 5HTs (2.6% vs. 8.2%; OR: 0.37; CI 0.21-0.65; p<0.01) but had similar AD (41.8% vs. 37.2%; OR: 1.2; CI 0.95-1.5; p=0.12). No differences in AD or DT were found among pts on HEC. Conclusions: Among early-stage BC pts initiating a MEC or HEC agent, PAL was associated with fewer CINV events, a lower (MEC) or equal (HEC) rate of delayed therapy, and equal adherence compared to other 5HTs.
Collapse
Affiliation(s)
- Hope S. Rugo
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | | | | | | | | |
Collapse
|
16
|
Knoth RL, Bolge SC, Kim E, Tran QV. Effect of inadequate response to treatment in patients with depression. Am J Manag Care 2010; 16:e188-e196. [PMID: 20690785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
OBJECTIVES To assess the effects of inadequate response to antidepressant treatment on healthcare resource utilization and on work productivity in patients diagnosed as having major depressive disorder (MDD). STUDY DESIGN This study used data from the 2006 US National Health and Wellness Survey, a cross-sectional survey of adults 18 years and older. METHODS Patients who self-reported a confirmed diagnosis of depression and were currently taking antidepressant medication were included in the analyses. Adequacy of antidepressant treatment response was determined from responses to the mental health domain of the 8-Item Short Form Health Survey (SF-8). Logistic regression analyses adjusted for demographics, comorbidity, and component scores on the SF-8 were used to determine the associations between inadequacy of treatment response and health outcomes. RESULTS Of 5988 patients who met the inclusion criteria for the study, 30.9% were classified as antidepressant treatment responders, 31.2% were partial responders, and 37.9% were nonresponders. Partial response and nonresponse to treatment were associated with greater likelihood of emergency department utilization (odds ratios [ORs], 1.26 and 1.54, respectively; P <.01 for both) and hospitalization (OR, 1.23; P = .05 and OR, 1.39; P <.01, respectively). Similarly, partial response and nonresponse were associated with lower likelihood of current employment (OR, 0.83; P = .01 and OR, 0.63; P <.01, respectively) and with greater likelihood of work productivity loss among the employed (ORs, 1.42 and 1.99, respectively; P <.01 for both). CONCLUSIONS Patients with MDD who failed to respond to antidepressant treatment as evidenced by poor self-reported mental health status used more healthcare resources, were less likely to be employed, and had more work productivity loss than those who responded to antidepressant therapy.
Collapse
|
17
|
Abstract
People often judge the probability of two events occurring together to be more probable than the less probable of each of these events occurring separately, thereby demonstrating the conjunction error. "Correct" responses are those in which participants rank a single-element statement
of low probability as more probable than a conjunction consisting of a low-probability statement and an additional statement. We demonstrated in two studies that task structure was related to the number of people who chose the single-element statement as more probable. However, relatively
few participants provided a rationale for their answer choice based on the conjunction rule. In a third study, responses on the answer choice and answer justification measures converged. In addition to serving as a sensitive dependent measure, participants' justifications when answering conjunction
problems may provide insight into their reasoning.
Collapse
|
18
|
Lew KH, Chang EY, Rajagopalan K, Knoth RL. The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface 2006; 19:41-6. [PMID: 17017312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
A retrospective analysis of electronic prescription and medical claims representing approximately 1.4 million managed care commercial health plan members with mental health benefits was conducted. The effect of patient adherence to traditional mood-stabilizer therapy (lithium, valproate, carbamazepine, lamotrigine, or oxcarbazepine) for bipolar disorder on mental health-related hospitalization was assessed among 1,399 patients (mean age, 42.9 yr; 66.3% female) studied. Reduced adherence to traditional mood-stabilizing therapy (< 80%) in patients with bipolar disorder was associated with significantly greater risk of mental health-related, emergency room visits (odds ratio, 1.98; 95% confidence interval, 1.38-2.84) and inpatient hospitalizations (odds ratio, 1.71; 95% confidence interval, 1.27-2.32), even after adjusting for age, gender, and comorbidity.
Collapse
Affiliation(s)
- Kim H Lew
- Health Informatics and Outcomes Research, Prescription Solutions, Irvine, California 92614-6223, USA
| | | | | | | |
Collapse
|
19
|
Affiliation(s)
- Russell L Knoth
- Prescription Solutions, 3515 Harbor Boulevard, Costa Mesa, California 92626, USA.
| | | | | |
Collapse
|
20
|
Abstract
The earthquake that hit Armenia, Colombia, on January 25, 1999, dramatically impacted the lives of thousands of people, including children and adolescents. This study used the Hispanic MMPI-A to clinically assess for ongoing psychopathology in a group of 59 adolescent earthquake victims. Their scores on the basic, content, and supplementary scales of the instrument were compared to those of a control group of 62 Colombian adolescents with similar socioeconomic, educational, and ethnic backgrounds. The results showed no clinically significant elevations for the earthquake victims indicating that the disaster had not resulted in diagnosable psychopathology. When compared to controls, earthquake victims showed significant elevations on D, Pt, and Sc indicating that they were mildly affected (but within the normal range) by the earthquake. The results are discussed in the context of cultural factors and the contemporary disaster and resiliency literature.
Collapse
Affiliation(s)
- Ronald L Scott
- Department of Psychology, Chapman University, Orange, California 92688, USA.
| | | | | | | |
Collapse
|
21
|
Knoth RL, Mair RG. Response latency and accuracy on a pretrained nonmatching-to-sample task in rats recovered from pyrithiamine-induced thiamine deficiency. Behav Neurosci 1991; 105:375-85. [PMID: 1907458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Rats were trained for 1,345 spatial nonmatching-to-sample (NMTS) trials, matched, assigned to pyrithiamine-induced thiamine deficiency (PTD) or control treatments, recovered, and re-tested for 400 trials of NMTS. The PTD model produced two bilaterally symmetrical lesions: one of medial thalamus that was centered on the internal medullary lamina (IML) and another involving the mammillary bodies. PTD rats with complete IML lesions showed a sharp drop in performance that persisted throughout posttreatment training. PTD rats with IML sparing were impaired immediately after treatment but improved to a level comparable to that of controls. For all animals, NMTS accuracy decreased for longer latency responses. PTD animals differed from controls primarily in the low frequency and inaccuracy of their short-latency (0-2.9 s) responses. The improvement of the PTD rats with IML sparing was marked by an increase in both the number and accuracy of short-latency responses.
Collapse
Affiliation(s)
- R L Knoth
- University of New Hampshire, Durham 03824
| | | |
Collapse
|
22
|
Mair RG, Otto TA, Knoth RL, Rabchenuk SA, Langlais PJ. Analysis of aversively conditioned learning and memory in rats recovered from pyrithiamine-induced thiamine deficiency. Behav Neurosci 1991; 105:351-9. [PMID: 1907456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Rats that had recovered from pyrithiamine-induced thiamine deficiency (PTD) were trained on tasks motivated by escape from mild footshock. On postmortem examination, the PTD model showed two consistent lesions: a bilaterally symmetrical lesion of the medial thalamus, which was centered on the internal medullary lamina (IML), and a lesion centered on the medial mammillary nuclei. PTD rats with IML lesions were impaired in learning a spatial nonmatching-to-sample (NMTS) task that was mastered without error by controls and PTD animals without IML lesions. These same animals were able to perform as well as controls on discrimination tasks based on either place or visual (light-dark) cues, although they made more errors than controls in reaching criterion in the initial place discrimination problem. These findings are consistent with findings from appetitively motivated tasks that PTD rats with IML lesions have an impaired capacity for working memory but not for reference memory.
Collapse
Affiliation(s)
- R G Mair
- Psychology Department, University of New Hampshire, Durham 03824
| | | | | | | | | |
Collapse
|
23
|
Mair RG, Knoth RL, Rabchenuk SA, Langlais PJ. Impairment of olfactory, auditory, and spatial serial reversal learning in rats recovered from pyrithiamine-induced thiamine deficiency. Behav Neurosci 1991; 105:360-74. [PMID: 1907457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Rats that had recovered from pyrithiamine-induced thiamine deficiency (PTD) were compared with controls for spatial, auditory, and olfactory serial reversal learning (SRL); spatial matching to sample (MTS); auditory go-no-go discrimination; and open-field exploration. PTD rats made more errors reaching criterion for SRL in all modalities but showed normal transfer effects between problems. PTD rats were also impaired in learning the go-no-go and MTS tasks and showed consistent alterations in exploratory activity. It is argued that the PTD rat, like human Korsakoff patients, have impairments of learning and memory (but spared capacity for reference memory) that extend across sensory modalities. Postmortem analyses showed normal indices of cortical cholinergic, noradrenergic, dopaminergic, and serotonergic function and consistent bilateral lesions of the thalamus, which were centered on the internal medullary lamina, and the medial mammillary nucleus.
Collapse
Affiliation(s)
- R G Mair
- Psychology Department, University of New Hampshire, Durham 03824
| | | | | | | |
Collapse
|
24
|
Mair RG, Knoth RL, Rabchenuk SA, Langlais PJ. Impairment of olfactory, auditory, and spatial serial reversal learning in rats recovered from pyrithiamine-induced thiamine deficiency. Behav Neurosci 1991. [DOI: 10.1037/0735-7044.105.3.360] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
25
|
Mair RG, Otto TA, Knoth RL, Rabchenuk SA, Langlais PJ. Analysis of aversively conditioned learning and memory in rats recovered from pyrithiamine-induced thiamine deficiency. Behav Neurosci 1991. [DOI: 10.1037/0735-7044.105.3.351] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
26
|
Knoth RL, Mair RG. Response latency and accuracy on a pretrained nonmatching-to-sample task in rats recovered from pyrithiamine-induced thiamine deficiency. Behav Neurosci 1991. [DOI: 10.1037/0735-7044.105.3.375] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|